BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naik H, Chan S, Vakilynejad M, Chen G, Loft H, Mahableshwarkar AR, Areberg J. A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder. Basic Clin Pharmacol Toxicol 2016;118:344-55. [DOI: 10.1111/bcpt.12513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Matsuno K, Nakamura K, Aritomi Y, Nishimura A. Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Clin Pharmacol Drug Dev 2018;7:319-31. [PMID: 28941196 DOI: 10.1002/cpdd.381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Miao J, Wang G, Hou J, Areberg J, Zhao Y, Højer AM, Ettrup A. Pharmacokinetics and Safety of Vortioxetine in the Chinese Population. Adv Ther 2019;36:3134-46. [PMID: 31552551 DOI: 10.1007/s12325-019-01092-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen G, Nomikos GG, Affinito J, Jacobson W, Zhao Z, Wang S, Xie J. Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Clinical Pharmacology in Drug Development 2018;7:880-8. [DOI: 10.1002/cpdd.577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Frederiksen T, Areberg J, Schmidt E, Bjerregaard Stage T, Brøsen K. Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine. Clin Pharmacol Ther 2021;109:150-9. [PMID: 32599653 DOI: 10.1002/cpt.1972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet 2018;57:673-86. [PMID: 29189941 DOI: 10.1007/s40262-017-0612-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 13.3] [Reference Citation Analysis]
6 Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. J Clin Psychopharmacol 2018;38:172-9. [DOI: 10.1097/jcp.0000000000000861] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 2018;96:247-59. [DOI: 10.1016/j.jpsychires.2017.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]